Can tobramycin inhalation be improved with a jet nebulizer?
Data on the pharmacokinetics of antibiotics after inhalation are limited. The aim of this pilot study was to assess the pharmacokinetics of tobramycin under optimalized and standardized aerosol circumstances and, furthermore, to be able to consider possible treatment of exacerbations with inhalation therapy. Six patients were studied after inhalation of 600 mg tobramycin. A jet nebulizer loaded with a 10% solution of tobramycin in water was used. The percentage of the dose that was systemically absorbed ranged from 1.0% to 16.6%. The maximum serum levels of tobramycin ranged from 0.77 mg/L to 3.63 mg/L (mean 1.70 +/- 1.01). The pharmacokinetic data were best described by a two-compartment model. Compared to intravenous administration, the long terminal half-life (mean 9.47 h +/- 3.28 h) could be explained by the slow absorption of tobramycin from the site of administration (flip-flop model). Despite standardized aerosol conditions, considerable interpatient variability was observed. However, the relatively low serum levels allow a further increase of the dose.
Le Brun
P P
PP
Central Hospital Pharmacy The Hague, The Netherlands.
Vinks
A A
AA
Touw
D J
DJ
Hekelaar
N
N
Mannes
G P
GP
Brimicombe
R W
RW
Frijlink
E H
EH
Heijerman
H G
HG
D000280:Administration, Inhalation; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008954:Models, Biological; D009330:Nebulizers and Vaporizers; D010865:Pilot Projects; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine
D000900:Anti-Bacterial Agents; D014031:Tobramycin